Portola Pharmaceuticals' (NASDAQ:PTLA) could have two commercial-stage drugs on the market next year, but turning them into top-sellers will require a lot of money. Is Portola Pharmaceuticals' balance sheet flush enough with cash to get its drugs across the finish line?
What's at stakeLast year, Portola Pharmaceuticals suffered two big setbacks that forced it to go longer without any product revenue. In March 2016, shares took a drubbing after management reported mixed results from a trial evaluating its anticoagulant betrixaban. In August, shareholders were dealt another blow when management reported receiving an FDA rejection letter for its anticoagulant antidote, AndexXa.
Image source: Getty Images.
This year, the company's shares are back on track after management told investors that the FDA won't require an advisory committee meeting prior to issuing a decision on betrixaban on June 24. Management also announced plans to refile AndexXa for approval in the second quarter, potentially allowing for a go/no-go decision by year's end.
Top 5 Stocks To Invest In Right Now: Full House Resorts, Inc.(FLL)
Advisors' Opinion:- [By Logan Wallace]
Huazhu Group (NASDAQ: HTHT) and Full House Resorts (NASDAQ:FLL) are both consumer discretionary companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, valuation, risk, analyst recommendations and institutional ownership.
Top 5 Stocks To Invest In Right Now: ANI Pharmaceuticals, Inc.(ANIP)
Advisors' Opinion:- [By Joseph Griffin]
Headlines about ANI Pharmaceuticals Inc Common Stock (NASDAQ:ANIP) have been trending somewhat negative recently, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. ANI Pharmaceuticals Inc Common Stock earned a media sentiment score of -0.08 on Accern’s scale. Accern also assigned news coverage about the specialty pharmaceutical company an impact score of 48.3270217581665 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
- [By Motley Fool Transcribing]
ANI Pharmaceuticals (NASDAQ:ANIP) Q4 2018 Earnings Conference CallFeb. 27, 2019 10:30 a.m. ET
Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:Operator
- [By Max Byerly]
Mallinckrodt (NYSE: MNK) and ANI Pharmaceuticals Inc Common Stock (NASDAQ:ANIP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, valuation, earnings and profitability.
- [By Joseph Griffin]
Canaccord Genuity set a $82.00 target price on ANI Pharmaceuticals (NASDAQ:ANIP) in a research report released on Tuesday morning. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.
- [By Max Byerly]
Virginia Retirement Systems ET AL reduced its position in ANI Pharmaceuticals Inc (NASDAQ:ANIP) by 59.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 13,100 shares of the specialty pharmaceutical company’s stock after selling 19,000 shares during the period. Virginia Retirement Systems ET AL’s holdings in ANI Pharmaceuticals were worth $590,000 at the end of the most recent reporting period.
Top 5 Stocks To Invest In Right Now: Equifax, Inc.(EFX)
Advisors' Opinion:- [By Max Byerly]
Effect.AI (CURRENCY:EFX) traded down 2.1% against the US dollar during the 24 hour period ending at 19:00 PM E.T. on September 10th. Over the last seven days, Effect.AI has traded down 28.3% against the US dollar. One Effect.AI token can now be bought for $0.0099 or 0.00000157 BTC on major exchanges including LATOKEN, BitMart, Bitbns and Switcheo Network. Effect.AI has a total market cap of $2.05 million and $33,817.00 worth of Effect.AI was traded on exchanges in the last 24 hours.
- [By Stephan Byrd]
Traders sold shares of Equifax Inc. (NYSE:EFX) on strength during trading on Monday. $14.23 million flowed into the stock on the tick-up and $53.87 million flowed out of the stock on the tick-down, for a money net flow of $39.64 million out of the stock. Of all stocks tracked, Equifax had the 30th highest net out-flow for the day. Equifax traded up $1.29 for the day and closed at $128.53
- [By Dan Caplinger]
Warren Buffett has gotten a lot of attention this week after the release of his annual letter to shareholders in Berkshire Hathaway (NYSE:BRK-A) (NYSE:BRK-B). But the Oracle of Omaha also made news for considering something he almost never does: selling off a part of his business. Meanwhile, testimony on Capitol Hill held some potential landmines for Equifax (NYSE:EFX), as the credit rating agency faced tough questions about data breaches.
- [By Max Byerly]
Legal & General Group Plc cut its position in Equifax Inc. (NYSE:EFX) by 11.6% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 550,710 shares of the credit services provider’s stock after selling 72,328 shares during the quarter. Legal & General Group Plc owned about 0.46% of Equifax worth $68,899,000 at the end of the most recent reporting period.
- [By Ethan Ryder]
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
Get Equifax alerts: Equifax Inc. (EFX) Receives Average Recommendation of “Hold” from Brokerages (americanbankingnews.com) After Equifax hack, credit freezes now free starting Sept. 21 (msn.com) How Financially Strong Is Equifax Inc (NYSE:EFX)? (finance.yahoo.com) Zacks: Analysts Anticipate Equifax Inc. (EFX) Will Post Quarterly Sales of $858.07 Million (americanbankingnews.com) $1.42 EPS Expected for Equifax Inc. (EFX) This Quarter (americanbankingnews.com)Several analysts have recently weighed in on the stock. ValuEngine raised shares of Equifax from a “sell” rating to a “hold” rating in a research note on Friday, June 8th. Zacks Investment Research cut shares of Equifax from a “hold” rating to a “sell” rating in a research note on Wednesday, June 27th. Morgan Stanley dropped their price target on shares of Equifax from $120.00 to $117.00 and set an “equal weight” rating for the company in a research note on Thursday, July 26th. Finally, JPMorgan Chase & Co. increased their price target on shares of Equifax from $135.00 to $150.00 and gave the company an “overweight” rating in a research note on Friday, July 27th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the company. Equifax presently has a consensus rating of “Hold” and an average target price of $123.54.
- [By Travis Hoium]
Companies that get a bad reputation from consumers often do so because they don't have to make their experience better to keep customers. Great examples of this are a cable company that operates as a monopoly in many areas, like Comcast (NASDAQ:CMCSA), or a bank you just can't get away from, like Wells Fargo (NYSE:WFC). Or even a company with all kinds of data about you that doesn't seem to manage that data carefully, like Equifax Inc. (NYSE:EFX).
Top 5 Stocks To Invest In Right Now: Marcus & Millichap, Inc.(MMI)
Advisors' Opinion:- [By Shane Hupp]
Marcus & Millichap (NYSE:MMI) was downgraded by analysts at JMP Securities from an “outperform” rating to a “market perform” rating in a report issued on Wednesday, Marketbeat reports.
- [By Logan Wallace]
Marcus & Millichap Inc (NYSE:MMI) major shareholder Phoenix Investments Holdings L sold 3,000 shares of Marcus & Millichap stock in a transaction that occurred on Monday, July 30th. The shares were sold at an average price of $40.27, for a total transaction of $120,810.00. Following the completion of the transaction, the insider now directly owns 16,532,215 shares in the company, valued at approximately $665,752,298.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
- [By Motley Fool Transcribers]
Marcus & Millichap Inc (NYSE:MMI)Q4 2018 Earnings Conference CallFeb. 20, 2019, 5:00 p.m. ET
Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:Operator
Top 5 Stocks To Invest In Right Now: Iteris, Inc.(ITI)
Advisors' Opinion:- [By Shane Hupp]
Get a free copy of the Zacks research report on Iteris (ITI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Shane Hupp]
Iteris (NASDAQ: ITI) and Napco Security Technologies (NASDAQ:NSSC) are both small-cap computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk.
- [By Max Byerly]
Iteris (NASDAQ:ITI) was downgraded by ValuEngine from a “buy” rating to a “hold” rating in a report released on Saturday.
Several other research analysts have also commented on the company. JMP Securities initiated coverage on Iteris in a research report on Thursday, January 25th. They issued an “outperform” rating and a $10.50 price objective on the stock. B. Riley set a $9.00 price objective on Iteris and gave the company a “buy” rating in a research report on Thursday, February 8th. Finally, Zacks Investment Research lowered Iteris from a “hold” rating to a “sell” rating in a research report on Wednesday, April 4th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Iteris has a consensus rating of “Buy” and a consensus price target of $8.75.
- [By Stephan Byrd]
Get a free copy of the Zacks research report on Iteris (ITI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment